Search Results

You are looking at 1 - 10 of 76 items for :

  • "cardiotoxicity" x
  • Refine by Access: All x
Clear All
Full access

Trastuzumab-Related Cardiac Dysfunction

Melinda L. Telli and Ronald M. Witteles

provided the first indication of potential cardiotoxicity risk associated with this agent. 4 An independent Cardiac Review and Evaluation Committee was subsequently convened to retrospectively review the cardiotoxicity data for patients treated with

Full access

QIM19-132: Trastuzumab Induced Cardiotoxicity: Are We Monitoring and Managing Appropriately?

Heather Katz, Hassaan Jafri, Emilia Cindy Leigh, Layana Biglow, Madhulika Urella, and Maria Tria Tirona

at 3-month intervals while on trastuzumab. Improvement to recognize when to hold trastuzumab to prevent cardiotoxicity is needed. Better documentation, easier accessibility to previous EF results, and a multidisciplinary team (breast navigator

Full access

Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Crystal S. Denlinger, Tara Sanft, K. Scott Baker, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Melissa Hudson, Nazanin Khakpour, Allison King, Divya Koura, Robin M. Lally, Terry S. Langbaum, Allison L. McDonough, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Javid J. Moslehi, Tracey O'Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, William Pirl, M. Alma Rodriguez, Kathryn J. Ruddy, Paula Silverman, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Nicole R. McMillian, and Deborah A. Freedman-Cass

ASCO, which concluded that no studies had systematically addressed the benefits of screening adult cancer survivors with a history of anthracyclines for cardiotoxicity. 44 The review also found no direct evidence showing the effectiveness of cardiac

Full access

CLO19-052: Incidence of Ribociclib-Associated Cardiac Conduction Abnormalities in Patients With Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer: A Combined Analysis of 3 Phase III Randomized Controlled Trials

Kyaw Z. Thein, Somedeb Ball, Sriman Swarup, Anita Sultan, Myo H. Zaw, Lukman Tijani, Sanjay Awasthi, Fred Hardwicke, and Catherine Jones

dysfunction due to prior cardiotoxic chemotherapies. In our meta-analysis, ribociclib was associated with significantly higher risk of QTc prolongation and the resultant dosing inconsistencies and discontinuation. Early detection of this potential adverse

Full access

CLO23-040: Electrocardiographic Findings in Cancer Patients Receiving Chemotherapy From the Colombian Coffee Triangle Region

Andres Garcia, David Medina, Alejandra Palacio, Andrés Vallejo, Luz Adriana Díaz, Juan Darío Franco, Tatiana Taborda, and María José Rojas

Background: Some antineoplastic agents are known for their cardiotoxicity, especially anthracyclines, used for breast cancer neoadjuvant chemotherapy and induction treatment for some hematological malignancies. Nevertheless, there is scarce

Full access

Highlights of the NCCN Oncology Research Program

overseen by the ORP. This feature highlights an NCCN study funded through the grant mechanism. Investigating the Role of African Genetic Ancestry in Cardiovascular Complications and Cardiotoxicity Among Patients With Prostate Cancer Post Treatment

Full access

A Change of Heart

Crystal S. Denlinger

outside of cancer highlights the difficulty in transitioning one's thinking from single-specialty focus to broader holistic clinical practice. In 2015, we introduced an algorithm on anthracycline-induced cardiotoxicity to the NCCN Guidelines for

Full access

Incident Cardiovascular Diseases Among Survivors of High-Risk Stage II–III Colorectal Cancer: A Cluster-Wide Cohort Study

Shing Fung Lee, Pui Lam Yip, Balamurugan A. Vellayappan, Cheng Ean Chee, Lea Choung Wong, Eric Yuk-Fai Wan, Esther Wai-Yin Chan, Chak-Fei Lee, Francis Ann-Shing Lee, and Miguel Angel Luque-Fernandez

capecitabine, are commonly used in adjuvant or neoadjuvant chemotherapy. 6 Among conventional cytotoxic agents, 5-FU is the most common one that causes cardiotoxicity, second only to anthracyclines. 7 Symptomatic acute cardiotoxicity occurs in up to 20% of

Full access


, Fox Chase Cancer Center ➤ Investigating the Role of African Genetic Ancestry in Cardiovascular Complications and Cardiotoxicity Among Prostate Cancer Patients Post Treatment With Androgen Deprivation Therapy • Balaji Tamarappoo, MD, PhD, Indiana

Full access

BPI20-018: Direction of Developing Cancer Survivorship Guidelines in Japan: An Expert Panel’s Consensus

Yutaka Matsuoka, Ryo Okubo, Yoichi Shimizu, Katsunori Tsuji, Narisawa Tomomi, Jiichiro Sasaki, and Hiroyuki Sasai

) Maintaining a non-smoking lifestyle; 6) Vaccinations; 7) Assessment, care, and management of the effects of anticancer drugs on the cardiovascular system (e.g., cardiotoxicity); 8) Assessment, care, and management of psychological pain; 9) Assessment, care